4.3 Review

Prevention and Care Programs Addressing the Growing Prevalence of Diabetes in China

Journal

CURRENT DIABETES REPORTS
Volume 16, Issue 12, Pages -

Publisher

CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-016-0821-8

Keywords

Diabetes management; Patient empowerment; Peer support; Integrated care

Funding

  1. Bayer
  2. Boehringer Ingelheim
  3. Daiichi-Sankyo
  4. Eli-Lilly
  5. GlaxoSmithKline
  6. Merck Sharp and Dohme
  7. Merck Serono
  8. Pfizer
  9. AstraZeneca
  10. Sanofi
  11. Novo-Nordisk
  12. Bristol-Myers Squibb

Ask authors/readers for more resources

According to a 2010 national survey, 11% of adults in China have diabetes, affecting 109.6 million individuals. The high prevalence of diabetes has been attributed to the aging of the population, the rapid adoption of energy-dense foods, and a reduction in physical activity. Collectively, these secular changes have created an obesogenic environment that can unmask diabetes in subjects with a genetic predisposition. The growing prevalence of maternal obesity, gestational diabetes, childhood obesity, and early-onset disease can lead to premature morbidity and mortality. Rising to meet these public health challenges, researchers in China have conducted randomized studies to demonstrate the benefits of lifestyle modification in preventing diabetes (the Da Qing Study), as well as that of team-based integrated care, using multiple strategies including peer support and information technology, in order to reduce hospitalizations, cardiovascular-renal complications, and premature deaths. With growing evidence supporting the benefits of these diabetes prevention and management programs, the next challenge is to use policies and systems to scale up the implementation of these programs through raising awareness, building capacity, and providing resources to reduce the human and socioeconomic burden of diabetes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available